The study began in June 2021 and will continue through May 2022 and is being conducted in over 600 hospitals in 52 countries.
The Solidarity Plus trial of the World Health Organization (WHO) will test four new treatments – artesunate, imatinib and infliximab – to treat COVID-19. Image credit: AP Illustration / Peter Hamlin
The Solidarity Plus trial of the World Health Organization (WHO) will enter its second phase. It will test four new therapies – artesunate, imatinib and infliximab – to treat COVID-19 .
The four drugs – remdesivir, hydroxychloroquine, lopinavir and interferon – were Evaluated during the last Solidarity Plus test where they found that they had “little or no effect on hospitalized patients” COVID-19 “
The World Health Organization’s Solidarity Plus trial is the world’s largest ongoing randomized control trial of potential COVID-19 medical. It represents the largest global collaboration among WHO member states.
With thousands of researchers and patients involved, this enables the trial to evaluate multiple treatments simultaneously using the same protocol. It also helps them get a solid estimate of the drug’s effect on mortality—even moderate effects.
New treatments are added to the guidelines while the WHO excludes those that are ineffective or proven unsafe or ineffective.
The study started in June 2021 and will run till May 2022. This is being done in over 600 hospitals in 52 countries.
ALSO READ: Clinical trials revelation: Everything you need to know about procedure, safety, eligibility
“Finding more effective and accessible therapeutics for COVID-19 There remains a critical need for patients, and WHO is proud to lead this global effort,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
There are three drugs:
- articulate Manufactured by Ipca and treats Malaria. This herb is derived from Artemisia annua. Artesunate is a derivative of Artemisinin that is considered very safe as it has been used to treat malaria for more than 30 years. Artemisia annua, commonly known as sweet wormwood, is a plant native to parts of Asia and North America. The standard dose used to treat malaria will be administered intravenously for seven days and its anti-inflammatory properties will be evaluated.
- imatinib Manufactured by Novartis and is a cancer treatment. It is an oral drug and preliminary experimental data suggest that it may “reverse pulmonary capillary leakage.” It will be given orally, daily for 14 days.
- infliximab Manufactured by Johnson & Johnson and treats diseases related to the immune system. It is a TNF alpha inhibitor, a chimeric monoclonal antibody that recognizes human TNF alpha. These types of anti-TNF drugs have been in use for more than 20 years. They have demonstrated efficacy and safety in restricting broad-spectrum inflammation, including the elderly population who are most clinically vulnerable. COVID-19 . A standard dose that patients with Crohn’s disease would receive would be administered intravenously.
Also read: Remdesivir, HCQ, HIV drug, Interferon ineffective in treatment in WHO’s Solidarity Trial COVID-19